Halda Therapeutics
Louise Giffin, Ph.D. has extensive work experience in the field of biotechnology and pharmaceuticals. Louise is currently serving as the Associate Director of Biology at Halda Therapeutics since April 2023. Prior to that, they worked at Boehringer Ingelheim as a Principal Scientist from October 2020 to April 2023 and as a Senior Scientist from August 2018 to September 2020.
Before joining Boehringer Ingelheim, Dr. Giffin worked at Heat Biologics, a clinical stage biotech company, where they held the positions of Scientist II from March 2018 to July 2018, Scientist from January 2017 to March 2018, and Postdoctoral Scientist from November 2015 to December 2016. Their role at Heat Biologics involved contributing to research, development, and discovery for the advancement of the company's technology platform.
Dr. Giffin's academic experience includes working as a Postdoctoral Research Fellow at the University of North Carolina at Chapel Hill from August 2015 to October 2015. Louise also served as a Graduate Student at the same institution from June 2009 to August 2015, where they worked on various research projects related to Kaposi's sarcoma associated herpesvirus (KSHV) and type I diabetes.
Before pursuing their graduate studies, Dr. Giffin gained research experience as an Undergraduate Researcher at Bucknell University from August 2007 to May 2009 and Rutgers University from May 2007 to August 2007.
Louise Giffin, Ph.D. completed their Bachelor of Science (BS) in Biochemistry and Cell Biology from Bucknell University in the years 2005 to 2009. Louise then pursued their higher education at the University of North Carolina at Chapel Hill from 2009 to 2015, earning their Doctor of Philosophy (Ph.D.) in Microbiology and Immunology. Additionally, Louise has obtained certifications in Current Good Manufacturing Practices (cGMP) and Good Laboratory Practices (GLP) - Certification Course on EPA and FDA Regulations from Wake Technical Community College. The specific dates of when they obtained these certifications are unavailable.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.